Promising combo for tough blood cancer hits snag: trial halted
NCT ID NCT04160052
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 23 times
Summary
This study tested two drugs, venetoclax and azacitidine, together in people with a serious type of bone marrow cancer called high-risk myelodysplastic syndrome (MDS). The goal was to find the best dose and see if the combo could shrink or control the cancer. The trial included 51 patients whose cancer had come back or not responded to prior treatment. However, the study was stopped early before completion.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROME are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.